Due to ethical restrictions imposed by the Ifakara Health Institute Institutional Review Board and National Health Research Ethics sub-Committee of the National Institute for Medical Research of Tanzania on protecting patient confidentiality, data cannot be made publicly available. Some of identified reasons include many unique identifiers such as TB district number which is the unique number assigned to TB patients who are diagnosed and treated at the health facility where also this study is being conducted. In addition, the dataset has the following variables that may breach patient privacy such as; place of treatment, gender, geographical position system (GPS) of residence of TB patients enrolled into this study, household size, and year of birth. Interested researchers should contact Dr. Frederick Haraka (<fharaka@ihi.or.tz>) for further information related to data access.

Introduction {#sec005}
============

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* remains a challenging disease to control. Indeed, over two billion people are estimated to be infected with *M*. *tuberculosis* worldwide \[[@pntd.0005342.ref001]\]. Moreover one billion people are infected with soil-transmitted helminths, schistosomes, filarial worms, and food-borne trematodes \[[@pntd.0005342.ref002]--[@pntd.0005342.ref004]\]. In 2014, an estimated 9.6 million new TB patients were notified and 1.5 million TB patients died from the disease \[[@pntd.0005342.ref001]\]. TB is a leading cause of deaths from an infectious disease \[[@pntd.0005342.ref005]\].

TB and helminthiases overlap geographically, particularly in areas where poverty persists, for example in countries of sub-Saharan Africa \[[@pntd.0005342.ref001],[@pntd.0005342.ref006]\]. Where TB and helminth infections co-occur, they can affect the same individual and thus exacerbate the course of disease \[[@pntd.0005342.ref006]\]. Several conditions such as diabetes mellitus, malnutrition, and malignancies are known to increase the risk of progressing from latent *M*. *tuberculosis* infection to active TB \[[@pntd.0005342.ref007]\]. Human immunodeficiency Virus (HIV)-induced immunodeficiency is by far the most important risk factor for developing TB \[[@pntd.0005342.ref001],[@pntd.0005342.ref008]\], but parasitic co-infections such as with helminths can also contribute to the development of TB \[[@pntd.0005342.ref009]--[@pntd.0005342.ref011]\]. Immune dysregulations caused by helminth infections are known to negatively affect the prognosis of HIV and malaria \[[@pntd.0005342.ref006],[@pntd.0005342.ref012]\]. The immune response to helminth infections is characterized by the induction of CD4^+^ T-helper 2 (Th2) and down-regulation of CD4^+^ T-helper 1 (Th1) cells \[[@pntd.0005342.ref012]--[@pntd.0005342.ref015]\]. This immunological imbalance has been suggested to increase the risk of progression from latent *M*. *tuberculosis* infection to active TB and to worsen the clinical outcomes.

We aimed to study the interaction between TB and helminth co-infections by comparing the prevalence of helminth infections, using a suite of diagnostic techniques, between TB patients and household contact controls without TB in an ongoing cohort study in Dar es Salaam, Tanzania, and to assess the effects of helminth infection on the clinical presentation and outcomes of TB disease.

Methods {#sec006}
=======

Ethics statement {#sec007}
----------------

The study protocol was approved by the institutional review board of the Ifakara Health Institute (IHI; reference no. IHI/IRB/No 04--2015) and the Medical Research Coordinating Committee of the National Institute of Medical Research (NIMR; reference no. NIMR/HQ/R.8c/Vol.I/357) in Tanzania, and the ethics committee of north-west and central Switzerland (EKNZ; reference no.: UBE-15/42). Written informed consent was obtained from all study participants. TB patients were treated according to the National TB and Leprosy Programme (NTLP) treatment guideline \[[@pntd.0005342.ref008]\]. Individuals with a *Schistosoma* spp. infection were treated with praziquantel (40 mg/kg). Other helminth infections were treated with albendazole (400 mg) immediately after diagnosis, as recommended by the national treatment guidelines \[[@pntd.0005342.ref016]\]. HIV-positive patients were clinically managed according to the Tanzania National HIV and acquired immune deficiency syndrome (AIDS) treatment guideline \[[@pntd.0005342.ref017]\].

Study setting {#sec008}
-------------

The study was conducted in the densely populated urban setting of Temeke district in Dar es Salaam, which is the economic capital of Tanzania. The population of Temeke is estimated at 1.4 million. In 2014, about one third of all TB patients from Dar es Salaam were notified in Temeke district (4,373; 32%) \[[@pntd.0005342.ref018]\]. The overall HIV prevalence in the general adult population in Dar es Salaam is 5.2% \[[@pntd.0005342.ref019]\]. The study area includes two TB sub-districts, Wailes I and Wailes II, whose patients are clinically managed at the Temeke district hospital and the two associated TB diagnostic and treatment centers of Tambukareli and Pasada \[[@pntd.0005342.ref020]\].

Study design {#sec009}
------------

The study was conducted within the frame of an ongoing prospective cohort study of TB patients and household contact controls in Dar es Salaam (TB-DAR). We assessed the association of TB and helminth infection in a case-control study design of TB patients (sputum smear-positives for acid-fast bacilli \[AFB\]) and household contact controls (Xpert MTB/RIF negative), who were matched by age (±5 years) and whenever possible by sex. We prospectively followed-up TB patients and assessed the clinical outcomes comparing TB patients with and without helminth infection at 6 and 12 months after recruitment.

Study population and sample size {#sec010}
--------------------------------

We consecutively enrolled study participants starting in November 2013 until October 2015 to reach the required sample size. Over this period, we included adult TB patients (≥18 years of age and sputum-smear positive) and household contact controls. Any individual living in the same household as the index TB patients enrolled in the study is referred to as a household contact control. Controls at recruitment were free of symptoms and signs suggestive of TB, healthy on physical examination, and had a negative Xpert MTB/RIF result (Cepheid; California, United States of America).

Assuming a helminth prevalence of 45% in TB patients and 26% in controls based on results from previous publications \[[@pntd.0005342.ref021]\] and a power of 80%, the target sample size was 109 study participants (for each group) to detect a prevalence difference of 19% between the two groups with a significance level of test 0.05, two-tailed and calculated with Stata version 14.0 (Stata Corp; Texas, United States of America).

Study procedures {#sec011}
----------------

TB patients and household contact controls were interviewed and underwent physical examination during recruitment at the study site (see under "Data Collection and Definitions"). We collected skinfold measurements from four body sites (biceps, triceps, subscapular, and suprailiac) using the Harpenden skinfold caliper \[[@pntd.0005342.ref022]\]. The percentage body fat was calculated as previously described \[[@pntd.0005342.ref023]\]. Household contacts with no symptoms or signs of TB submitted a sputum sample for Gene Xpert MTB/RIF to rule-out TB. We collected blood, stool, and urine samples from TB patients and controls for subsequent laboratory investigations. Chest X-rays for TB patients were done at the Temeke district hospital and were interpreted by an experienced board certified radiologist who was blinded to patients' clinical data. Trained field workers collected geographic coordinates (global positioning system \[GPS\]) from the patients' homes using Samsung Tab 4 android tablets (Samsung; Suwon, South Korea).

Laboratory procedures {#sec012}
---------------------

### Microbiological investigations {#sec013}

A patient was considered as having TB when any of the two submitted sputum samples were positive for AFB by staining sputum smears using the Ziehl-Nielsen (ZN) method, and a positive mycobacterial culture. Sputum smear microscopy was done at the Temeke district hospital under continuous quality control by the central tuberculosis reference laboratory (Dar es Salaam, Tanzania). AFB smear-positive results were graded according to World Health Organization/International Union Against Tuberculosis and Lung Disease (WHO/IUATLD) guidelines: "scanty" with 1--9 AFB per 100 oil immersion fields; "1+" with 10--99 AFB per 100 immersion fields; "2+" with 1--10 AFB per 1 immersion field, and "3+" with \>10 AFB per immersion field \[[@pntd.0005342.ref008],[@pntd.0005342.ref024]\]. To rule out TB among household controls, an additional sputum sample from TB patients and controls was sent to the TB laboratory at the Bagamoyo Research and Training Center (BRTC), IHI, for GeneXpert MTB/RIF (controls) and for culture on Löwenstein-Jensen media (TB patients and controls).

### Helminthological investigations {#sec014}

For the diagnosis of helminth infections, single stool and urine samples were collected from each participant before the start of TB treatment (TB patients) and at the time of enrolment (controls). All stool and urine samples were transferred to the Helminth Unit at BRTC and examined for helminth infections using standardized, quality-controlled procedures as described elsewhere \[[@pntd.0005342.ref025]--[@pntd.0005342.ref027]\]. The Kato-Katz (triplicate thick smears per stool sample) and the FLOTAC methods were used to diagnose *Ascaris lumbricoides*, hookworm, *S*. *mansoni*, and *Trichuris trichiura* infections. The Baermann method was used to identify *Strongyloides stercoralis* infections \[[@pntd.0005342.ref028]\]. The adhesive tape test was used to diagnose Enterobius vermicularis infections \[[@pntd.0005342.ref026]\]. In addition, a rapid point-of-care circulating cathodic antigen (POC-CCA) urine cassette test was employed for the diagnosis of *S*. *mansoni* \[[@pntd.0005342.ref029]\]. The urine filtration method was applied to detect *S*. *haematobium* infections \[[@pntd.0005342.ref026]\]. For quality control, 10% of Kato-Katz slides were randomly selected and re-examined by a second reader.

### Blood testing {#sec015}

In line with national HIV testing algorithms, screening was done using the Alere Determine HIV rapid test (Alere, USA). The Uni-gold HIV (Trinity Biotech; Wicklow, Ireland) rapid test served as a confirmatory test in case of a positive screening test. The CD4^+^ T-cells counts were determined using a FACSCount machine (Becton Dickinson Biosciences; California, United States of America). A full blood cell count was done with a MS4 Vet hematology analyzer (Diamond Diagnostics; Massachusetts, United States of America). All blood tests were performed at the Temeke district hospital laboratory, which is under supervision and quality control by the regional laboratory technician.

Data collection and definitions {#sec016}
-------------------------------

We collected socio-demographic indicators including age, sex, ethnicity, education, and household income. Anthropometric data included weight, height, and skinfold measurements. Clinical data collected pertained to presenting symptoms of TB patients, TB treatment category, and treatment outcomes. Laboratory data included ZN sputum smear results and Gene Xpert MTB/RIF results, helminth species infections, HIV status, full blood cell count, and CD4^+^ cell count. All study participants were asked about their use of anthelmintic treatment in the last 12 months prior to the enrollment into the study. Study data were captured by electronic case report forms using the open-source data collection software ODK on Android PC tablets \[[@pntd.0005342.ref030]\]. Data management was done using the *e*Management tool "odk_planner", as previously described \[[@pntd.0005342.ref030]\]. Data were uploaded to a password protected secure server with regular back-ups.

In order to grade the clinical severity of TB, we adopted a previously published clinical TB score \[[@pntd.0005342.ref031]\], with the following modification: 12 points TB score parameters instead of 13 points as tachycardia was not systematically measured. The following TB score parameters were used: (i) coughing; (ii) hemoptysis; (iii) chest pain; (iv) dyspnea; (v) night sweating; (vi) anemic conjunctivae; (vii) positive finding at auscultation; (viii) axillary temperature \>37.0°C; (ix) mid upper arm circumference (MUAC) \<220 mm; (x) MUAC \<200 mm; (xi) body mass index (BMI) \<18 kg/m^2^; and (xii) BMI \<16 kg/m^2^. TB score was then categorized into mild (score of 1--5) and severe (score of ≥6). Low BMI was defined as BMI \<18 kg/m^2^; high sputum bacterial load as AFB sputum smear result ≥2+ (quantitative scoring), which correlates with GeneXpert Ct values \[[@pntd.0005342.ref032]\]. To assess the clinical outcomes among TB patients, we defined poor gain as a change in absolute body weight (\<7 and ≥7 kg), BMI (\<2.6 and ≥2.6 kg/m^2^) and body fat (\<0 and ≥0%) from recruitment to month 6 of follow-up.

"Any helminth infection" was defined as infection with any of the following helminth species: *A*. *lumbricoides*, *E. vermicularis*, hookworm, *Hymenolepis diminuta*, *S*. *haematobium*, *S*. *mansoni*, *S*. *stercoralis* and *T*. *trichiura*. High occupational risk for schistosomiasis was defined as working in rice fields, sand harvesting, washing cars, and fishing in freshwater. The intensity of helminth infection was defined according to WHO classification \[[@pntd.0005342.ref033]\]. The average egg counts from the triplicate Kato-Katz thick smears per stool sample and per individual were multiplied by a factor of 24 to obtain eggs per gram (EPG) of stool \[[@pntd.0005342.ref025]\].

Statistical analysis {#sec017}
--------------------

We compared the characteristics of TB patients and household contact controls at the time of TB diagnosis or enrolment. The prevalence of helminth infection was calculated from the generalized estimations equation adjusting for clustering at the household level. We used multilevel mixed-effects logistic regression with random intercepts at the level of households to assess risk factors for helminth infection. To assess risk factors for TB, we compared cases and controls using unconditional logistic regression because not all TB cases could be assigned a control. In addition, we also performed conditional logistic regression among matched pairs to confirm the results. Additional analyses assessed the association of TB and with specific helminth species separately. We also examined whether the association between the presence of a helminth infection and a recent history of deworming drugs depended on HIV infection status by including an interaction term in the logistic regression model. Among TB patients, logistic regression models were used to study associations between helminth infection and clinical presentation at the time of TB diagnosis (such as TB score, high sputum bacterial load, lung infiltration, and cavitation), and to study the association between helminth infection and clinical outcomes after 6 months of TB treatment (change in absolute weight, BMI, and percentage body fat). Associations were expressed as crude odds ratios (ORs) and adjusted ORs (aORs). All analyses were performed in Stata version 14.0 (Stata Corp; Texas, United States of America).

We used the geographic coordinates of the TB patients' homes to analyze the spatial distribution of TB and helminth co-infections. The prevalence of helminths and helminth species was analyzed at the ward level for optimal readability. The average area per ward in the Dar es Salaam region is 15.5 km^2^ \[[@pntd.0005342.ref019]\]. The maps were produced using the software package ArcGIS Desktop version 10.2 (ESRI; California, United States of America) and the shape files from the National Bureau of Statistics of Tanzania \[[@pntd.0005342.ref034]\].

Results {#sec018}
=======

Characteristics of study participants {#sec019}
-------------------------------------

A total of 597 TB patients and 375 household contact controls were included. [Table 1](#pntd.0005342.t001){ref-type="table"} summarizes the socio-demographic and clinical characteristics of TB patients and controls. The study participants' flow diagram is shown in [Fig 1](#pntd.0005342.g001){ref-type="fig"}. Among all study participants, the median age was 33 years (interquartile range \[IQR\]: 26--41 years) and 60.2% (585/972) were men. HIV prevalence was 20.4% (95% confidence interval (CI): 17.9--23.0%). TB patients were more frequently male compared with controls (68.8% \[411/597\] *vs*. 46.4% \[174/375\]), HIV-positive (27.3% \[163\] *vs*. 9.3% \[35\]), and smokers (18.1% \[108\] *vs*. 8.8% \[33\]). TB patients also had a lower median BMI (18.3 kg/m^2^, IQR: 16.5--20.4 kg/m^2^ *vs*. 23.9 kg/m^2^, IQR: 21.6--28.1 kg/m^2^) and a lower median hemoglobin level (11.3 g/dl, IQR: 9.9--12.7 g/dl *vs*. 12.8 g/dl, IQR: 11.5--14.1 g/dl). The patient characteristics, stratified by HIV status, are shown in [S1 Table](#pntd.0005342.s001){ref-type="supplementary-material"}.

![Study participants' flow diagram.](pntd.0005342.g001){#pntd.0005342.g001}
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###### Socio-demographic and clinical characteristics of tuberculosis (TB) patients and household contact controls without TB.

![](pntd.0005342.t001){#pntd.0005342.t001g}

  -------------------------------------------------------------------------------------------------------------------------
  Characteristics                                               Total\              TB patient\         Controls\
                                                                (n = 972)           (n = 597)           (n = 375)
  ------------------------------------------------------------- ------------------- ------------------- -------------------
  **Age in years, median (IQR)**                                33 (26--41)         33 (26--40)         33 (26--42)

  **Age groups (years)**                                                                                

   18--24                                                       194 (20.0)          107 (17.9)          87 (23.2)

   25--34                                                       347 (35.7)          226 (37.9)          121 (32.3)

   35--44                                                       266 (27.4)          169 (28.3)          97 (25.9)

   ≥45                                                          165 (17.0)          95 (15.9)           70 (18.7)

  **Sex**                                                                                               

   Female                                                       387 (39.8)          186 (31.2)          201 (53.6)

   Male                                                         585 (60.2)          411 (68.8)          174 (46.4)

  **HIV status**                                                                                        

   Negative                                                     774 (79.6)          434 (72.7)          340 (90.7)

   Positive                                                     198 (20.4)          163 (27.3)          35 (9.3)

  **Education level**                                                                                   

   No/primary                                                   806 (82.9)          500 (83.8)          306 (81.6)

   Secondary/University                                         166 (17.1)          97 (16.2)           69 (18.4)

  **Occupation**                                                                                        

   Unemployed                                                   349 (35.9)          204 (34.2)          145 (38.7)

   Employed                                                     623 (64.1)          393 (65.8)          230 (61.3)

  **Smoking status**                                                                                    

   No                                                           831 (85.5)          489 (81.9)          342 (91.2)

   Yes                                                          141 (14.5)          108 (18.1)          33 (8.8)

  **People in the household**                                                                           

   ≤3                                                           731 (75.2)          442 (74.0)          289 (77.1)

   \>3                                                          241 (24.8)          155 (26.0)          86 (22.9)

  **Household income per month (US\$)**                                                                 

   ≤100                                                         763 (78.5)          473 (79.2)          290 (77.3)

   \>100                                                        209 (21.5)          124 (20.8)          85 (22.7)

  **Body weight at diagnosis, \[in kg\], (IQR)**                54 (48--61)         51 (46--57)         59 (53--67)

  **BMI (kg/m^2^), median (IQR)**                               20.0 (17.6--23.4)   18.3 (16.6--20.4)   23.9 (21.6--28.1)

  **BMI categories (kg/m^2^)**                                                                          

   Underweight \<18.5                                           337 (34.7)          318 (53.3)          19 (5.1)

   Normal, 18.5--24.9                                           454 (46.7)          256 (42.9)          198 (52.8)

   Overweight 25.0--29.9                                        119 (12.2)          21 (3.5)            98 (26.1)

   Obese ≥30                                                    62 (6.4)            2 (0.3)             60 (16.0)

  **Body fat (%)**                                              10.1 (7.7--14.7)    9.5 (6.8--13.7)     11.5 (8.5--17.0)

  **MUAC (cm), median (IQR)**                                   24.3 (22.7--26.2)   23.3 (22.0--25.3)   25.3 (23.7--28.0)

  **Waist hip ratio, median (IQR)**                             0.89 (0.86--0.94)   0.89 (0.86--0.94)   0.89 (0.86--0.94)

  **Occupational risk**[^a^](#t001fn001){ref-type="table-fn"}                                           

   No                                                           521 (54.2)          322 (54.2)          199 (54.1)

   Yes                                                          441 (45.8)          272 (45.8)          169 (45.9)

  **Individual deworming (past 12 months)**                                                             

   Yes                                                          797 (82.0)          484 (81.1)          313 (83.5)

   No                                                           175 (18.0)          113 (18.9)          62 (16.5)

  **Hb level (g/dl), median (IQR)**                             12 (10.4--13.3)     11.3 (9.9--12.7)    12.8 (11.5--14.1)
  -------------------------------------------------------------------------------------------------------------------------

^a^ Occupational risk for acquiring schistosomiasis (working in rice fields, sand harvesting, washing cars, and fishing)

BMI, body mass index; HIV, human immunodefiency virus; Hb, hemoglobin level; IQR, inter-quartile range; MUAC, mid-upper arm circumference; US\$, United States dollars (1 US\$ = 2,190 Tanzanian Shillings in March 2016)

Prevalence and risk factors for helminth infection {#sec020}
--------------------------------------------------

Among all participants, the prevalence of any helminth infection was 29.5% (95% CI: 26.7--32.6%). *S*. *stercoralis* (16.5%, 161) was the predominant helminth species, followed by hookworm (9.0%, 87), *S*. *mansoni* (5.7%, 55) and *S*. *haematobium* (2.0%, 19). Overall, TB patients were more frequently co-infected with any helminth species compared with controls (OR 1.34, 95% CI: 1.00--1.78, p = 0.048; [Table 2](#pntd.0005342.t002){ref-type="table"}). The prevalence of helminth infection was lower in HIV-positive (22.7%, 45) compared with HIV-negative study participants (31.3%, 242; [S1 Table](#pntd.0005342.s001){ref-type="supplementary-material"}). Similarly, helminth infection was lower among TB patients co-infected with HIV (22.7%, 37) compared with HIV-negative TB patients (35.3%, 153; [S2 Table](#pntd.0005342.s002){ref-type="supplementary-material"}). We found that most study participants had light-intensity helminth infection. For example, 96.4% (54) of study participants had light-intensity hookworm infection as determined by the Kato-Katz method ([S3 Table](#pntd.0005342.s003){ref-type="supplementary-material"}). The prevalence and geographic distribution of species-specific helminth infections in the study area is shown in [S1 Fig](#pntd.0005342.s012){ref-type="supplementary-material"}.

10.1371/journal.pntd.0005342.t002

###### Frequency distribution of helminth infections, stratified by TB patients and household contact controls.
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  Helminth infection             All          TB patients   Controls     Comparing TB patients and controls[^a^](#t002fn001){ref-type="table-fn"}   
  ------------------------------ ------------ ------------- ------------ -------------------------------------------------------------------------- -------
  **Any helminth**               287 (29.5)   190 (31.8)    97 (25.9)    1.34 (1.00--1.78)                                                          0.048
  **Helminth species**                                                                                                                              
   *Strongyloides stercoralis*   161 (16.6)   111 (18.6)    50 (13.3)    1.48 (1.03--2.13)                                                          0.032
   Hookworm                      87 (9.0)     55 (9.2)      32 (8.5)     1.09 (0.69--1.72)                                                          0.72
   *Ascaris lumbricoides*        6 (0.6)      3 (0.5)       3 (0.8)      0.63 (0.13--3.12)                                                          0.57
   *Enterobius vermicularis*     5 (0.5)      1 (0.2)       4 (1.1)      NA                                                                         NA
   *Trichuris trichiura*         9 (0.9)      6 (1.0)       3 (0.8)      1.25 (0.31--5.06)                                                          0.75
   *Hymenolepis diminuta*        2 (0.2)      1 (0.2)       1 (0.3)      NA                                                                         NA
   *Schistosoma* spp.            70 (7.2)     49 (8.2)      21 (5.6)     1.51 (0.89--2.56)                                                          0.13
    *Schistosoma mansoni*        55 (5.7)     40 (6.7)      15 (4.0)     1.72 (0.94--3.17)                                                          0.079
    *Schistosoma haematobium*    19 (2.0)     11 (1.8)      8 (2.1)      0.86 (0.34--2.16)                                                          0.75
  **Helminth infection**                                                                                                                            0.13
   None                          685 (70.5)   407 (68.2)    278 (74.1)   1                                                                          
   Mono-infection                237 (24.4)   158 (26.5)    79 (21.1)    1.37 (1.00--1.86)                                                          
   Infection with ≥2 species     50 (5.1)     32 (5.3)      18 (4.8)     1.21 (0.67--2.21)                                                          

^a^ Estimates from an unadjusted mixed-effect models with household as a random intercept

NA, not applicable; OR, odds ratio

Study participants with occupational risk for acquiring schistosomiasis, such as working in rice fields, sand harvesting, washing cars, and fishing had higher odds of being infected with any helminth species (aOR 1.42, 95% CI: 1.04--1.95, p = 0.029). HIV-positive patients were less likely to be infected with any helminth species (aOR 0.57, 95% CI: 0.37--0.87, p = 0.010; [Table 3](#pntd.0005342.t003){ref-type="table"}). Study participants who did not take anthelmintic treatment in the past 12 months did not have significant higher odds of being co-infected with any helminth species (aOR 1.35, 95% CI: 0.92--1.99, p = 0.12). There was no statistically significant interaction between the effects of HIV infection and deworming status on TB incidence (P-value from test for interaction: 0.5). When analyzing the risk factors for helminth infection separately for TB patients and household controls without TB, we found similar results (see [S5](#pntd.0005342.s005){ref-type="supplementary-material"} and [S6](#pntd.0005342.s006){ref-type="supplementary-material"} Tables).

10.1371/journal.pntd.0005342.t003

###### Risk factors for any helminth infection among TB patients and household controls without TB.
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  Characteristic                                                Helminth infection, n (%)   Unadjusted   Adjusted                                        
  ------------------------------------------------------------- --------------------------- ------------ ------------------- ------- ------------------- -------
  **Participant**                                                                                                            0.054                       0.18
   Controls                                                     97 (33.8)                   278 (40.6)   1.00                        1.00                
   TB patients                                                  190 (66.2)                  407 (59.4)   1.35 (1.00--1.82)           1.29 (0.88--1.87)   
  **Age group (years)**                                                                                                      0.30                        0.46
   18--24                                                       50 (17.4)                   144 (21.0)   1.00                        1.00                
   25--34                                                       115 (40.1)                  232 (33.9)   1.46 (0.96--2.23)           1.38 (0.89--2.17)   
   35--44                                                       75 (26.1)                   191 (27.9)   1.13 (0.72--1.78)           1.11 (0.68--1.82)   
   ≥45                                                          47 (16.4)                   118 (17.2)   1.16 (0.70--1.92)           1.18 (0.69--2.03)   
  **Sex**                                                                                                                    0.003                       0.24
   Female                                                       93 (32.4)                   294 (42.9)   1.00                        1.00                
   Male                                                         194 (67.6)                  391 (57.1)   1.60 (1.17--2.18)           1.23 (0.87--1.75)   
  **HIV status**                                                                                                             0.022                       0.010
   Negative                                                     242 (84.3)                  532 (77.7)   1.00                        1.00                
   Positive                                                     45 (15.7)                   153 (22.3)   0.63 (0.43--0.94)           0.57 (0.37--0.87)   
  **BMI category (kg/m^2^)**                                                                                                 0.077                       0.47
   BMI ≥18                                                      175 (61.0)                  460 (67.2)   1.00                        1.00                
   BMI \<18                                                     112 (39.0)                  225 (32.8)   1.32 (0.97--1.79)           1.14 (0.79--1.64)   
  **Education level**                                                                                                        0.28                        0.50
   No/primary                                                   243 (84.7)                  563 (82.2)   1.00                        1.00                
   Secondary/University                                         44 (15.3)                   122 (17.8)   0.80 (0.53--1.20)           0.86 (0.55--1.34)   
  **Employment status**                                                                                                      0.13                        0.42
   Unemployed                                                   93 (32.4)                   256 (37.4)   1.00                        1.00                
   Employed                                                     194 (67.6)                  429 (62.6)   1.28 (0.93--1.76)           1.16 (0.81--1.65)   
  **Number of people in the household**                                                                                      0.66                        0.97
   ≤3                                                           218 (76.0)                  69 (24.0)    1.00                        1.00                
   \>3                                                          513 (74.9)                  172 (25.1)   0.93 (0.65--1.32)           0.99 (0.69--1.42)   
  **Household income per month (US\$)**                                                                                      0.47                        0.75
   ≤100                                                         229 (79.8)                  534 (78.0)   1.00                        1.00                
   \>100                                                        58 (20.2)                   151 (22.0)   0.87 (0.60--1.26)           0.94 (0.63--1.40)   
  **Individual deworming (past 12 months)**                                                                                  0.043                       0.12
   Yes                                                          224 (78.0)                  573 (83.6)   1.00                        1.00                
   No                                                           63 (22.0)                   112 (16.4)   1.48 (1.01--2.15)           1.35 (0.92--1.99)   
  **Occupational risk**[^a^](#t003fn001){ref-type="table-fn"}                                                                0.009                       0.029
   No                                                           136 (47.7)                  385 (56.9)   1.00                        1.00                
   Yes                                                          149 (52.3)                  292 (43.1)   1.50 (1.11--2.03)           1.42 (1.04--1.95)   

^a^ Occupational risk for acquiring schistosomiasis (working in rice fields, sand harvesting, washing cars, and fishing)

BMI, body mass index; HIV, human immunodeficieny virus; US\$, United States dollars (1 US\$ = 2,190 Tanzanian Shillings in March 2016)

Multilevel mixed-effects logistic regression model with household as a random intercept, adjusted for TB status, age-groups, sex, HIV status, BMI, education level, employment status, number of people living in the same household, individual deworming status, occupational risk, and income level.

Note: interaction between the effect of HIV and deworming status on the risk for any helminth infection: p = 0.50

Helminth infection as a risk factor for TB {#sec021}
------------------------------------------

Multiple logistic regression models adjusted for patient characteristics and known risk factors for TB showed that any helminth infection was not statistically significantly associated with TB (aOR 1.26, 95% CI: 0.88--1.80, p = 0.22, [Table 4](#pntd.0005342.t004){ref-type="table"} and [S7 Table](#pntd.0005342.s007){ref-type="supplementary-material"}). However, when analyzing each helminth species separately, we found that *S*. *mansoni* infection was significantly associated with TB (aOR 2.15, 95% CI: 1.03--4.45, p = 0.040), but there was no significant association between TB and *S*. *stercoralis* or hookworm infection ([S8 Table](#pntd.0005342.s008){ref-type="supplementary-material"}). Other co-factors that were significantly associated with TB included: male sex, HIV co-infection, smoking, living in a household with ≥3 people, and a low BMI ([Table 4](#pntd.0005342.t004){ref-type="table"}). The unadjusted and adjusted ORs for any helminth infection and *S*. *mansoni* are shown in [S7 Table](#pntd.0005342.s007){ref-type="supplementary-material"}. Results were more pronounced when using a conditional logistic regression model ([S9 Table](#pntd.0005342.s009){ref-type="supplementary-material"}).

10.1371/journal.pntd.0005342.t004

###### Associations of TB disease with helminth infection and other patient characteristics.

![](pntd.0005342.t004){#pntd.0005342.t004g}

  Characteristics                                                                         Any helminth infection (n = 972)   *S*. *mansoni* infection (n = 972)                         
  ------------------------------------------------------------- ------------ ------------ ---------------------------------- ------------------------------------ --------------------- ---------
  **Helminth infection**                                                                                                     0.22                                                       0.040
   No                                                           407 (68.2)   278 (74.1)   1.00                                                                    1.00                  
   Yes                                                          190 (31.8)   97 (25.9)    1.26 (0.88--1.80)                                                       2.15 (1.03--4.45)     
  **Age group (years)**                                                                                                      0.49                                                       0.25
   18--24                                                       107 (17.9)   87 (23.2)    1.00                                                                    1.00                  
   25--34                                                       226 (37.9)   121 (32.3)   1.22 (0.77--1.94)                                                       1.24 (0.78--1.97)     
   35--44                                                       169 (28.3)   97 (25.9)    1.00 (0.60--1.67)                                                       1.02 (0.61--1.7)      
   ≥45                                                          95 (15.9)    70 (18.7)    0.85 (0.48--1.48)                                                       0.88 (0.51--1.54)     
  **Sex**                                                                                                                    \<0.001                                                    \<0.001
   Female                                                       186 (31.2)   201 (53.6)   1.00                                                                    1.00                  
   Male                                                         411 (68.8)   174 (46.4)   3.12 (2.13--4.56)                                                       3.16 (2.16--4.63)     
  **HIV status**                                                                                                             \<0.001                                                    \<0.001
   Negative                                                     434 (72.7)   340 (90.7)   1.00                                                                    1.00                  
   Positive                                                     163 (27.3)   35 (9.3)     6.18 (3.83--9.95)                                                       6.23 (3.86--10.05)    
  **Education level**                                                                                                        0.55                                                       0.57
   No/primary                                                   500 (83.8)   306 (81.6)   1.00                                                                    1.00                  
   Secondary/University                                         97 (16.2)    69 (18.4)    1.15 (0.73--1.80)                                                       1.14 (0.72--1.79)     
  **Employment status**                                                                                                      0.63                                                       0.66
   Unemployed                                                   204 (34.2)   145 (38.7)   1.00                                                                    1.00                  
   Employed                                                     393 (65.8)   230 (61.3)   0.91 (0.62--1.33)                                                       0.92 (0.63--1.34)     
  **Smoking status**                                                                                                         0.012                                                      0.011
   No                                                           489 (81.9)   342 (91.2)   1.00                                                                    1.00                  
   Yes                                                          108 (18.1)   33 (8.8)     1.92 (1.15--3.21)                                                       1.95 (1.16--3.25)     
  **Number of people in the household**                                                                                      0.018                                                      0.015
   ≤3 people                                                    442 (74.0)   289 (77.1)   1.00                                                                    1.00                  
   \>3 people                                                   155 (26.0)   86 (22.9)    1.58 (1.08--2.30)                                                       1.60 (1.09--2.34)     
  **Household income per month (US\$)**                                                                                      0.85                                                       0.95
   ≤100                                                         473 (79.2)   290 (77.3)   1.00                                                                    1.00                  
   \>100                                                        124 (20.8)   85 (22.7)    1.04 (0.69--1.56)                                                       1.01 (0.68--1.52)     
  **BMI category (kg/m^2^)**                                                                                                 \<0.001                                                    \<0.001
   BMI ≥18                                                      279 (46.7)   318 (53.3)   1.00                                                                    1.00                  
   BMI \<18                                                     356 (94.9)   19 (5.1)     23.20 (13.91--38.69)                                                    23.52 (14.1--39.24)   
  **Occupational risk**[^a^](#t004fn002){ref-type="table-fn"}                                                                0.24                                                       0.26
   No                                                           322 (54.2)   199 (54.1)   1.00                                                                    1.00                  
   Yes                                                          272 (45.8)   169 (45.9)   0.82 (0.59--1.15)                                                       0.83 (0.59--1.15)     
  **Individual deworming (past 12 months)**                                                                                  0.20                                                       0.21
   Yes                                                          484 (81.1)   313 (83.5)   1.00                                                                    1.00                  
   No                                                           113 (18.9)   62 (16.5)    0.75 (0.48--1.16)                                                       0.76 (0.49--1.17)     

BMI, body mass index; CI, confidence interval; HIV, human immunodeficieny virus; OR, odds ratio; US\$, United States dollars (1 US\$ = 2,190 Tanzanian Shillings in March 2016)

^a^ Occupational risk for acquiring schistosomiasis (working in rice fields, sand harvesting, washing cars, and fishing)

Logistic regression model for TB disease status as the outcome. Model adjusted for any helminth infection/*S*. *mansoni*, age, sex, HIV status, BMI, education level, employment status, smoking status, number of people living in the same household, individual deworming status, helminth risk occupation and income level.

The full table with unadjusted and adjusted odds ratios is shown in the Supplementary Information ([S7 Table](#pntd.0005342.s007){ref-type="supplementary-material"}).

Effect of helminth infection on clinical presentation and disease severity in TB patients {#sec022}
-----------------------------------------------------------------------------------------

TB patients co-infected with any helminth infection were more likely than helminth un-infected TB patients to present with hemoptysis (74 \[38.9%\] *vs*. 123 \[30.2%\]), had higher median hemoglobin levels (11.7 g/dl, IQR: 10.1--13.0 g/dl *vs*. 11.3 g/dl, IQR: 9.8--12.5 g/dl) and higher median eosinophil counts (0.2, IQR: 0.1--0.4 cells/μl *vs*. 0.1, IQR: 0.05--0.2 cells/μl; [Table 5](#pntd.0005342.t005){ref-type="table"}). TB patients co-infected with *S*. *mansoni* were more likely to have lower sputum bacterial load than helminth-uninfected TB patients (aOR 2.63; 95% CI: 1.38--5.26, p = 0.004). Furthermore, we found that TB patients co-infected with *S*. *mansoni* tended to have fewer lung cavities, although this association lacked statistical significance (aOR 0.41, 95% CI: 0.12--1.16, p = 0.088; [Table 6](#pntd.0005342.t006){ref-type="table"}). There were no statistically significant differences in radiological features between TB patients with and without any helminth infection as shown in [S10 Table](#pntd.0005342.s010){ref-type="supplementary-material"}.

10.1371/journal.pntd.0005342.t005

###### Patient characteristics of TB patients infected and not infected with helminths at the time of TB diagnosis.
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  Characteristics                                                    Total               TB and helminth     TB only             p-value
  ------------------------------------------------------------------ ------------------- ------------------- ------------------- --------------------------------------------
  **Age, median (IQR) (years)**                                      33 (26--40)         31 (26--39)         34 (27--40)         0.22
  **Age groups (years)**                                                                                                         0.13
   18--24                                                            107 (17.9)          35 (18.4)           72 (17.7)           
   25--34                                                            226 (37.9)          81 (42.6)           145 (35.6)          
   35--44                                                            169 (28.3)          42 (22.1)           127 (31.2)          
   ≥45                                                               95 (15.9)           32 (16.8)           63 (15.5)           
  **Sex**                                                                                                                        0.007
   Female                                                            186 (31.2)          45 (23.7)           141 (34.6)          
   Male                                                              411 (68.8)          145 (76.3)          266 (65.4)          
  **HIV status**                                                                                                                 0.003
   Negative                                                          434 (72.7)          153 (80.5)          281 (69.0)          
   Positive                                                          163 (27.3)          37 (19.5)           126 (31.0)          
  **CD4^+^ count, cells/ml**[^a^](#t005fn003){ref-type="table-fn"}   202 (94--273)       185 (90--259)       203 (100--273)      0.74
  **Education level**                                                                                                            0.49
   No/primary                                                        500 (83.8)          162 (85.3)          338 (83.0)          
   Secondary/University                                              97 (16.2)           28 (14.7)           69 (17.0)           
  **Occupation**                                                                                                                 0.99
   Unemployed                                                        204 (34.2)          65 (34.2)           139 (34.2)          
   Employed                                                          393 (65.8)          125 (65.8)          268 (65.8)          
  **Number of people in the household**                                                                                          0.89
   ≤3 people                                                         442 (74.0)          140 (73.7)          302 (74.2)          
   \> 3 people                                                       155 (26.0)          50 (26.3)           105 (25.8)          
  **Smoking status**                                                                                                             \<0.004
   No                                                                489 (81.9)          143 (75.3)          346 (85.0)          
   Yes                                                               108 (18.1)          47 (24.7)           61 (15.0)           
  **Household income per month (US\$)**                                                                                          0.45
   ≤100                                                              473 (79.2)          154 (81.1)          319 (78.4)          
   \>100                                                             124 (20.8)          36 (18.9)           88 (21.6)           
  **Body weight (kg), median (IQR)**                                 51 (46--57)         50.9 (46--56)       51.7 (46--57.5)     0.40
  **BMI (kg/m^2^), median(IQR)**                                     18.3 (16.6--20.4)   18.2 (16.5--20.2)   18.5 (16.6--20.4)   0.22
  **BMI (kg/m^2^) groups, n (%)**                                                                                                0.40[^b^](#t005fn004){ref-type="table-fn"}
   Underweight \<18.5                                                318 (53.3)          108 (56.8)          210 (51.6)          
   Normal, 18.5--24.9                                                256 (42.9)          78 (41.1)           178 (43.7)          
   Overweight 25.0--29.9                                             21 (3.5)            4 (2.1)             17 (4.2)            
   Obese ≥30                                                         2 (0.3)             0                   2 (0.5)             
  **Body fat (%)**                                                   9.5 (6.8--13.7)     9.1 (6.0--12.7)     9.8 (7.4--14.0)     0.008
  **MUAC (cm), median (IQR)**                                        23.3 (22.0--25.3)   23.7 (22.0--25.0)   23.3 (22.0--25.7)   0.99
  **Waist hip ratio, median (IQR)**                                  0.89 (0.85--0.94)   0.89 (0.85--0.94)   0.89 (0.86--0.94)   0.75
  **Occupational risk**                                                                                                          0.095
   No                                                                322 (54.2)          93 (49.2)           229 (56.5)          
   Yes                                                               272 (45.8)          96 (50.8)           176 (43.5)          
  **Individual deworming (past 12 months)**                                                                                      0.013
   Yes                                                               484 (81.1)          143 (75.3)          341 (83.8)          
   No                                                                113 (18.9)          47 (24.7)           66 (16.2)           
  **Symptoms**[^c^](#t005fn005){ref-type="table-fn"}                                                                             
   Cough                                                             594 (99.5)          189 (99.5)          405 (99.5)          0.96
   Fever                                                             551 (92.3)          174 (91.6)          377 (92.6)          0.65
   Weight loss                                                       573 (96.0)          181 (95.3)          392 (96.3)          0.54
   Night sweats                                                      566 (94.8)          184 (96.8)          382 (93.9)          0.13
   Hemoptysis                                                        197 (33.0)          74 (38.9)           123 (30.2)          0.035
  **TB score, median (IQR)**                                         5 (4--6)            5 (4--6)            5 (4--6)            0.22
   TB score (0--5)                                                   372 (62.3)          115 (60.5)          257 (63.1)          
   TB score (6--12)                                                  225 (37.7)          75 (39.5)           150 (36.9)          
  **TB treatment categories**                                                                                                    0.40
   Retreatment                                                       14 (2.3)            3 (1.6)             11 (2.7)            
   New patients                                                      583 (97.7)          187 (98.4)          396 (97.3)          
  **Blood parameters** [^c^](#t005fn005){ref-type="table-fn"}                                                                    
   Hemoglobin level                                                  11.3 (9.9--12.7)    11.7 (10.1--13)     11.3 (9.8--12.5)    0.044
   Eosinophil, cells per μl[^d^](#t005fn006){ref-type="table-fn"}    0.15 (0.06--0.32)   0.2 (0.1--0.4)      0.1 (0.05--0.2)     0.003

AFB, acid-fast bacilli; BMI, body mass index; HIV, human immunodefiency virus; IQR, interquartile range; MUAC, mid-upper arm circumference; US\$, United States dollars (1 US\$ = 2,190 Tanzanian Shillings in March 2016)

Helminth infection occupation risk (working in rice fields, sand harvesting, washing cars, and fishing)

^a^ TB patient co-infected with HIV and have CD4^+^ count values (n = 80)

^b^ Fisher's exact test

^c^"Symptoms", and "blood parameters": categories not mutually exclusive

^d^ TB patients with an available full blood count result (n = 322)

10.1371/journal.pntd.0005342.t006

###### Effect of helminth infection on the clinical severity and clinical presentation in TB patients at the time of TB diagnosis.
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  Helminth infection                                                      Severe TB score[^a^](#t006fn002){ref-type="table-fn"}   High sputum bacterial load[^b^](#t006fn003){ref-type="table-fn"}   Lung infiltration   Lung cavitation                                                   
  ----------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------ ------------------- ----------------- ------------------- ------- ------------------- -------
  **Any helminth infection**                                                                                                      0.55                                                                                   0.12                                  0.42                        0.82
   No                                                                     1.00                                                                                                                       1.00                                  1.00                        1.00                
   Yes                                                                    1.12 (0.78--1.61)                                                                                                          0.75 (0.51--1.08)                     0.82 (0.50--1.33)           0.95 (0.60--1.50)   
  ***Strongyloides stercoralis***[^c^](#t006fn004){ref-type="table-fn"}                                                           0.44                                                                                   0.39                                  0.17                        0.76
   No                                                                     1.00                                                                                                                       1.00                                  1.00                        1.00                
   Yes                                                                    1.19 (0.76--1.86)                                                                                                          0.82 (0.52--1.29)                     1.56 (0.83--2.92)           1.09 (0.62--1.91)   
  ***Schistosoma mansoni*** [^d^](#t006fn005){ref-type="table-fn"}                                                                0.75                                                                                   0.004                                 0.15                        0.088
   No                                                                     1.00                                                                                                                       1.00                                  1.00                        1.00                
   Yes                                                                    0.89 (0.45--1.78)                                                                                                          0.37 (0.19--0.72)                     0.51 (0.21--1.27)           0.41 (0.12--1.16)   
  **Hookworm**[^e^](#t006fn006){ref-type="table-fn"}                                                                              0.55                                                                                   0.40                                  0.086                       0.54
   No                                                                     1.00                                                                                                                       1.00                                  1.00                        1.00                
   Yes                                                                    1.20 (0.67--2.15)                                                                                                          0.77 (0.42--1.42)                     0.51 (0.23--1.10)           0.79 (0.37--1.69)   
  **Multiple infections**                                                                                                         0.82                                                                                   0.020                                 0.19                        0.40
   None                                                                   1.00                                                                                                                       1.00                                  1.00                        1.00                
   Mono                                                                   1.13 (0.77--1.67)                                                                                                          0.88 (0.59--1.31)                     0.85 (0.51--1.43)           1.06 (0.66--1.72)   
   Double or more                                                         1.04 (0.48--2.22)                                                                                                          0.34 (0.16--0.73)                     0.67 (0.24--1.84)           0.50 (0.17--1.44)   

Logistic regression model adjusted for age, sex, HIV infection, and smoking status.

^a^ TB score (mild \[score of 1--5\] and severe \[score of 6--12\])

^b^ Sputum bacterial load (according to qualitative AFB smear microscopy grading): mild (scanty and 1+) and severe (≥+2)

^c^ 79 TB patients with any helminth infection other than *S*. *stercoralis* were excluded

^d^ 150 TB patients with helminth co-infection other than *S*. *mansoni* were excluded

^e^ 72 TB patients with helminth co-infection other than hookworm were excluded

Effect of helminth infection on clinical outcomes in TB patients {#sec023}
----------------------------------------------------------------

Overall, 81.7% (273 TB patients) were cured at the end of TB treatment (at 6 months), 17.4% (58) completed treatment (AFB smear results not available at 6 months, but documented completion of treatment), and 0.9% (3) were treatment failures (positive AFB smear result at 6 months). We found no significant associations between helminth infection (at time of recruitment) and poor gain in absolute weight (aOR 0.89, 95% CI: 0.55--1.45, p = 0.63), BMI (aOR 0.74, 95% CI: 0.46--1.21, p = 0.23), and body fat percentage (aOR 0.92, 95% CI: 0.55--1.56, p = 0.78) after 6 months on TB treatment, as shown in [S11 Table](#pntd.0005342.s011){ref-type="supplementary-material"}.

Discussion {#sec024}
==========

We present findings on the prevalence and association of TB and helminth co-infection among adult TB patients and household contact controls in a highly-urbanized setting of Dar es Salaam, Tanzania. We found that *S*. *mansoni* infection was a risk factor for TB disease. This association remained significant after adjustment for other known risk factors for TB, such as HIV infection, smoking, and underweight \[[@pntd.0005342.ref035]\]. None of the other investigated helminth species or the surrogate measure of "any helminth infection" were significantly associated with TB. Importantly, associations between any helminth co-infection and TB were reported in previous epidemiologic studies \[[@pntd.0005342.ref021],[@pntd.0005342.ref036],[@pntd.0005342.ref037]\], as well as in experimental work using animal or macrophage infection models \[[@pntd.0005342.ref009],[@pntd.0005342.ref013],[@pntd.0005342.ref015]\]. In line with our findings, a recent study with human peripheral mononuclear cells exposed to *M*. *tuberculosis* and *S*. *mansoni* antigens showed that *S*. *mansoni*-induced CD4^+^ T cells disrupt the control of *M*. *tuberculosis* in infected macrophages \[[@pntd.0005342.ref009]\].

Several studies in humans suggested that helminth infections may increase the risk for progression of latent *M*. *tuberculosis* infection to active TB \[[@pntd.0005342.ref015],[@pntd.0005342.ref021],[@pntd.0005342.ref037]\] as well as for exacerbating the disease \[[@pntd.0005342.ref015]\]. However, the results of these studies are conflicting, and no differentiation at the helminth species level was made in these analyses. Indeed, the hypothesis of a helminth species-specific impact on the host response is supported by a recent systematic review, which revealed a trend toward an association between a decrease in HIV viral loads and treatment for *S*. *mansoni*, but not for other helminth species \[[@pntd.0005342.ref038]\]. A case-control study from Ethiopia also found an association between TB and helminth infections, and the association was stronger in patients that were infected with multiple helminth species \[[@pntd.0005342.ref021]\]. The small number of study participants with *S*. *mansoni* infection (31 among TB cases, nine among controls) may have masked an association between TB and schistosomiasis in that study \[[@pntd.0005342.ref021]\]. In contrast, a cohort study from India showed no difference in TB incidence rates in helminth-infected and helminth-free individuals after 2.5 years of follow-up \[[@pntd.0005342.ref039]\].

We also found that *S*. *mansoni*, but not other helminth species, was associated with the clinical presentation among TB patients. Patients co-infected with *S*. *mansoni* had lower sputum bacterial loads at the time of TB diagnosis than *S*. *mansoni*-negative TB patients. Similarly, a study in Ethiopia observed lower sputum bacterial loads at TB diagnosis in TB patients co-infected with any helminth species \[[@pntd.0005342.ref040]\]. Interestingly, our observation in TB patients co-infected with *S*. *mansoni* resembles the paucibacillary disease in HIV-positive individuals with severe immunosuppression, who frequently have negative or low bacterial *M*. *tuberculosis* loads in the sputum compared with HIV-negative patients \[[@pntd.0005342.ref040],[@pntd.0005342.ref041]\]. Hence, the helminth-induced Th1 immunological impairment might have an effect on the sputum bacterial load. Moreover, TB patients with an impaired host immune system rarely present with lung cavitation resulting in fewer *M*. *tuberculosis* bacilli being expectorated in the sputum \[[@pntd.0005342.ref040],[@pntd.0005342.ref041]\]. This is in line with our findings that TB patients co-infected with *S*. *mansoni* tended to present less frequently with lung cavitations compared with *S*. *mansoni*-negative TB patients. Any helminth co-infection did not appear to have an effect on clinical outcomes during follow-up. We found no evidence for an effect of helminth co-infection on the gain in the percentage of body fat and BMI after 6 months (e.g., at the time of completed TB treatment). This might be explained by the fact that the administration of anthelmintic treatment offered to the study participants after diagnosis might have reversed the Th1 immune response \[[@pntd.0005342.ref015]\], and thus attenuated the effect of helminth infections on clinical outcomes. However, the effect of a reversal of the Th1 immune response could be minimal as the anthelmintic drugs target the worms \[[@pntd.0005342.ref042]\], which are less immunogenic compared with deposited *S*. *mansoni* eggs \[[@pntd.0005342.ref009]\].

We found that TB patients had a higher crude prevalence of helminth infections, as compared with household contact controls. The higher prevalence of helminth infections among TB patients could be the result of the pathogenic role of helminth infection in the progression from *M*. *tuberculosis* infection to active TB. The higher prevalence of helminth co-infection in TB patients has also been noted in other studies from different settings \[[@pntd.0005342.ref009],[@pntd.0005342.ref043]\]. For example, a study conducted in Ethiopia reported a higher prevalence of helminth infection among TB patients as compared with household contact controls \[[@pntd.0005342.ref021]\]. Overall, the prevalence of helminth infection in our study was 32% and lower compared with the 71% observed in the latter study \[[@pntd.0005342.ref021]\]. It is conceivable that the high proportion of self-reported previous use of anthelmintic drugs in our study (approximately 80%) could have reduced the overall prevalence of helminth infection. Hence, we may have underestimated the effects of helminth infection seen in our study.

We also found that occupation exposing people to regular water contacts (for instance rice field workers, sand harvesters, car washers, and fishermen) were associated with helminth infections. Being exposed to freshwater bodies and being involved in water-related activities have previously been reported to increase the risk of helminth infections \[[@pntd.0005342.ref044]\]. In the current study, HIV-positive individuals were less likely to be co-infected with helminths. A lower prevalence of helminth infections in HIV-positive patients has also been reported in a study conducted in Mwanza in northern Tanzania, which is a highly endemic area for helminthiases \[[@pntd.0005342.ref045]\]. Of note, current clinical practice in Tanzania is to treat any helminth infection in HIV-positive patients at enrolment into HIV care and in case of clinical suspicion of helminth infection during follow-up, as specified in the HIV/AIDS management guideline \[[@pntd.0005342.ref017]\]. The use of anthelmintic drugs is safe and might be beneficial in HIV-positive patients by possibly reducing the HIV-RNA viral load and subsequently improving clinical outcomes \[[@pntd.0005342.ref046]\]. Furthermore, cotrimoxazole preventive therapy (CPT), which is recommended for HIV-positive patients, has also been reported to have limited anthelmintic properties \[[@pntd.0005342.ref043],[@pntd.0005342.ref047]\]. This might explain the lower prevalence of helminth infection among HIV-positive individuals in our study \[[@pntd.0005342.ref017]\].

Our research has several strengths and limitations that warrant consideration. An important strength of our study is the large sample size and the recruitment of both TB patients and household contact controls with similar socioeconomic profiles and exposure patterns to both TB and helminth infection. Our findings may well apply to other settings with a similar prevalence of TB, HIV, and helminth infections in sub-Saharan Africa. Furthermore, we used recommended TB diagnostics and a suite of standardized, quality-controlled helminth diagnostics, which have comparable diagnostic performance to resource-intensive molecular test assays \[[@pntd.0005342.ref025]\].

Study limitations include the following. First, this is an observational study which cannot establish a causal relationship between helminth infections and TB disease. Second, we could not fully verify whether or not the household contact controls were latently infected with *M*. *tuberculosis*, which is a prerequisite to develop TB. However, because Dar es Salaam is a high-burden setting for TB with considerable risk of transmission, and because living with a TB patient is a strong risk factor for TB \[[@pntd.0005342.ref035]\], it is reasonable to assume that the controls have previously been exposed and infected with *M*. *tuberculosis*. Third, we did not check the helminth infection status for TB patients during and after completion of TB treatment, which could influence the clinical outcomes. However, we do not expect a high helminth re-infection rate after 6 months in our study area \[[@pntd.0005342.ref048]\]. Fourth, we did not use molecular diagnostics such as polymerase chain reaction (PCR) which might have identified some more cases, but one of our previous studies revealed that also PCR approaches miss in particular very light intensity infections. Moreover, its performance and sensitivity vary with the helminth species under examination \[[@pntd.0005342.ref025]\]. Hence, also a PCR cannot be considered as the diagnostic gold-standard.

In conclusion, co-infection with *S*. *mansoni*, but not other helminth species, was found to be an independent risk factor for active TB in our study and was associated with the clinical presentation in TB patients. These findings suggest a role for *S*. *mansoni*, or helminth infection in general, in immunomodulation of human TB. Treatment of helminth infections should be considered in the clinical management of TB patients, and helminthiasis control/elimination through preventive chemotherapy might prove to be useful as an additional component of TB control programs. Further research is needed to establish the underlying mechanisms, and compare helminth-induced immune regulation by different helminth species. Prospective cohort studies that evaluate the effect of preventive anthelmintic chemotherapy on the incidence of *M*. *tuberculosis* infection and active TB could further help to understand the interaction between these diseases at the population level. Helminthiasis control measures, in combination with traditional TB control strategies, could potentially contribute to the global efforts to reduce TB incidence by 80% until 2030, as stipulated in WHO's ambitious End TB Strategy \[[@pntd.0005342.ref005]\].
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